Suppression of human pancreatic cancer cell proliferation by AGN194204, an RXR-selective retinoid

Carcinogenesis

Volumn 25, Issue 8, 2004, Pages 1377-1385

  Balasubramanian, Sivaprakasam ^a   Chandraratna, Roshantha A S ^b   Eckert, Richard L ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 [5,6 DIHYDRO 5,5 DIMETHYL 8 (4 METHYLPHENYL) 2 NAPHTHYL]ETHYNYL]BENZOIC ACID; 4 [2 METHYL 1 (5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 2 NAPHTHYL) 1 PROPENYL]BENZOIC ACID; AGN 194204; AGN 195393; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CELL MARKER; CISPLATIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN E; CYTOTOXIC AGENT; FLUOROURACIL; GAMMA INTERFERON; GEMCITABINE; PROTEIN P27; RETINOIC ACID RECEPTOR; RETINOID DERIVATIVE; RETINOID X RECEPTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; CDK2 PROTEIN, HUMAN; CDK4 PROTEIN, HUMAN; CDK6 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE; DEOXYCYTIDINE; DRUG DERIVATIVE; LIGAND; ONCOPROTEIN; RETINOID; TETRALIN DERIVATIVE; TRANSCRIPTION FACTOR; UNSATURATED FATTY ACID;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL COUNT; CELL DEATH; CELL PROLIFERATION; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN DEGRADATION; CELL CYCLE; CELL DIVISION; DOSE RESPONSE; METABOLISM; PANCREAS TUMOR; PLASMID; PROTEIN BINDING; TIME; TUMOR CELL LINE; WESTERN BLOTTING;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; CDC2-CDC28 KINASES; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CYCLIN D1; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; CYCLIN-DEPENDENT KINASES; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS, UNSATURATED; FLUOROURACIL; HUMANS; INTERFERON TYPE II; INTERFERON-ALPHA; LIGANDS; PANCREATIC NEOPLASMS; PLASMIDS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTORS; RETINOIDS; TETRAHYDRONAPHTHALENES; TIME FACTORS; TRANSCRIPTION FACTORS;

EID: 4344703257     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/bgh122     Document Type: Article

References (48)

1. Arbuck,S.G. (1990) Chemotherapy for pancreatic cancer. Baillieres Clin. Gastroenterol., 4, 953-968.
2. Rosenberg,L. (2000) Pancreatic cancer: a review of emerging therapies. Drugs, 59, 1071-1089.
3. Petkovich,M., Brand,N.J., Krust,A. and Chambon,P. (1987) A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature, 330, 444-450.
4. Brand,N., Petkovich,M., Krust,A., Chambon,P., de The,H., Marchio,A., Tiollais,P. and Dejean,A. (1988) Identification of a second human retinoic acid receptor. Nature, 332, 850-853.
5. Mangelsdorf,D.J., Umesono,K., Kliewer,S.A., Borgmeyer,U., Ong,E.S. and Evans,R.M. (1991) A direct repeat in the cellular retinol-binding protein type II gene confers differential regulation by RXR and RAR. J. Cell Biochem., 66, 555-561.
6. Mangelsdorf,D.J., Borgmeyer,U., Heyman,R.A., Zhou,J.Y., Ong,E.S., Oro,A.E., Kakizuka,A. and Evans,R.M. (1992) Characterization of three RXR genes that mediate the action of 9-cis retinoic acid. Genes Dev., 6, 329-344.
7. Westin,S., Rosenfeld,M.G. and Glass,C.K. (2000) Nuclear receptor coactivators. Adv. Pharmacol., 47, 89-112.
8. Heyman,R.A., Mangelsdorf,D.J., Dyck,J.A., Stein,R.B., Eichele,G., Evans,R.M. and Thaller,C. (1992) 9-Cis retinoic acid is a high affinity ligand for the retinoid X receptor. J. Cell Biochem., 68, 397-406.
9. Zelent,A., Krust,A., Petkovich,M., Kastner,P. and Chambon,P. (1989) Cloning of murine alpha and beta retinoic acid receptors and a novel receptor gamma predominantly expressed in skin. Nature, 339, 714-717.
10. Chandraratna,R.A. (1996) Tazarotene - first of a new generation of receptor-selective retinoids. Br. J. Dermatol., 135 (suppl. 49), 18-25.
11. Standeven,A.M., Thacher,S.M., Yuan,Y.D., Escobar,M., Vuligonda,V., Beard,R.L. and Chandraratna,R.A. (2001) Retinoid X receptor agonist elevation of serum triglycerides in rats by potentiation of retinoic acid receptor agonist induction or by action as single agents. Biochem. Pharmacol., 62, 1501-1509.
12. Nagpal,S. and Chandraratna,R.A. (2000) Recent developments in receptor-selective retinoids. Curr. Pharm. Des, 6, 919-931.
13. Thacher,S.M., Nagpal,S., Klein,E.S., Arefieg,T., Krasinski,G., DiSepio,D., Agarwal,C., Johnson,A., Eckert,R.L. and Chandraratna,R.A. (1999) Cell type and gene-specific activity of the retinoid inverse agonist AGN 193109: divergent effects from agonist at retinoic acid receptor gamma in human keratinocytes [In Process Citation]. Cell Growth Differ., 10, 255-262.
14. Pettersson,F., Dalgleish,A.G., Bissonnette,R.P. and Colston,K.W. (2002) Retinoids cause apoptosis in pancreatic cancer cells via activation of RAR-gamma and altered expression of Bcl-2/Bax. Br. J. Cancer, 87, 555-561.
15. Pettersson,F., Colston,K.W. and Dalgleish,A.G. (2001) Retinoic acid enhances the cytotoxic effects of gemcitabine and cisplatin in pancreatic adenocarcinoma cells. Pancreas, 23, 273-279.
16. Kawa,S., Nikaido,T., Aoki,Y., Zhai,Y., Kumagaya,T., Furihata,K., Fujii,S. and Kiyosawa,K. (1997) Arotinoid mofarotene (RO40-8757) up-regulates p21 and p27 during growth inhibition of pancreatic cancer cell lines. Int. J. Cancer, 72, 906-911.
17. Rosewicz,S., Stier,U., Brembeck,F., Kaiser,A., Papadimitriou,C.A., Berdel,W.E., Wiedenmann,B. and Riecken,E.O. (1995) Retinoids: effects on growth, differentiation, and nuclear receptor expression in human pancreatic carcinoma cell lines. Gastroenterology, 109, 1646-1660.
18. Recchia,F., Sica,G., Casucci,D., Rea,S., Gulino,A. and Frati,L. (1998) Advanced carcinoma of the pancreas: phase II study of combined chemotherapy, beta-interferon, and retinoids. Am. J. Clin. Oncol., 21, 275-278.
19. Riecken,E.O. and Rosewicz,S. (1999) Retinoids in pancreatic cancer. Ann. Oncol., 10 (suppl. 4), 197-200.
20. Strickland,S., Breitman,T.R., Frickel,F., Nurrenbach,A., Hadicke,E. and Sporn,M.B. (1983) Structure-activity relationships of a new series of retinoidal benzoic acid derivatives as measured by induction of differentiation of murine F9 teratocarcinoma cells and human HL-60 promyelocytic leukemia cells. Cancer Res., 43, 5268-5272.
21. Johnson,A.T., Klein,E.S., Gillett,S.J., Wang,L., Song,T.K., Pino,M.E. and Chandraratna,R.A. (1995) Synthesis and characterization of a highly potent and effective antagonist of retinoic acid receptors. J. Med. Chem., 38, 4764-4767.
22. Teng,M., Duong,T.T., Klein,E.S., Pino,M.E. and Chandraratna,R.A. (1996) Identification of a retinoic acid receptor alpha subtype specific agonist. J. Med. Chem., 39, 3035-3038.
23. Agarwal,C., Chandraratna,R.A., Johnson,A.T., Rorke,E.A. and Eckert,R.L. (1996) AGN193109 is a highly effective antagonist of retinoid action in human ectocervical epithelial cells. J. Biol. Chem., 271, 12209-12212.
24. Haller,D.G. (2003) Chemotherapy for advanced pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys., 56, 16-23.
25. Giguere,V., Ong,E.S., Segui,P. and Evans,R.M. (1987) Identification of a receptor for the morphogen retinoic acid. Nature, 330, 624-629.
26. Johnson,A. and Chandraratna,R.A. (1999) Novel retinoids with receptor selectivity and functional selectivity. Br. J. Dermatol., 140 (suppl. 54), 12-17.
27. Thacher,S.M., Standeven,A.M., Athanikar,J., Kopper,S., Castilleja,O., Escobar,M., Beard,R.L. and Chandraratna,R.A. (1997) Receptor specificity of retinoid-induced epidermal hyperplasia: effect of RXR-selective agonists and correlation with topical irritation. J. Pharmacol. Exp. Ther., 282, 528-534.
28. Wu,K., Zhang,Y., Xu,X.C. et al. (2002) The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res., 62, 6376-6390.
29. Wu,K., Kim,H.T., Rodriquez,J.L., Hilsenbeck,S.G., Mohsin,S.K., Xu,X.C., Lamph,W.W., Kuhn,J.G., Green,J.E. and Brown,P.H. (2002) Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol. Biomarkers Prev., 11, 467-474.
30. Rosenberg,L. and Lipsett,M. (2003) Biotherapeutic approaches to pancreatic cancer. Expert. Opin. Biol. Ther., 3, 319-337.
31. Albrechtsson,E., Ohlsson,B. and Axelson,J. (2002) The expression of retinoic acid receptors and the effects in vitro by retinoids in human pancreatic cancer cell lines. Pancreas, 25, 49-56.
32. Vickers,S.M., Sampson,L.K., Ying,W. and Phillips,J.O. (1997) Receptor-dependent growth inhibition of human pancreatic cancer by 9-cis retinoic acid. J. Gastrointest. Surg., 1, 174-181.
33. Egawa,N., Maillet,B., VanDamme,B., De Greve,J. and Kloppel,G. (1996) Differentiation of pancreatic carcinoma induced by retinoic acid or sodium butyrate: a morphological and molecular analysis of four cell lines. Virch. Arch., 429, 59-68.
34. Rosewicz,S., Brembeck,F., Kaiser,A., Marschall,Z.V. and Riecken,E.O. (1996) Differential growth regulation by all-trans retinoic acid is determined by protein kinase C alpha in human pancreatic carcinoma cells. Endocrinology, 137, 3340-3347.
35. Kaiser,A., Wolf-Breitinger,M., Albers,A., Dorbic,T., Wittig,B., Riecken,E.O. and Rosewicz,S. (1998) Retinoic acid receptor gamma1 expression determines retinoid sensitivity in pancreatic carcinoma cells. Gastroenterology, 115, 967-977.
36. Brembeck,F.H., Kaiser,A., Detjen,K., Hotz,H., Foitzik,T., Buhr,H.J., Riecken,E.O. and Rosewicz,S. (1998) Retinoic acid receptor alpha mediates growth inhibition by retinoids in rat pancreatic carcinoma DSL-6A/C1 cells. Br. J. Cancer, 78, 1288-1295.
37. Fujimoto,K., Hosotani,R., Doi,R., Wada,M., Lee,J.U., Koshiba,T., Miyamoto,Y., Tsuji,S., Nakajima,S. and Imamura,M. (1999) Induction of cell-cycle arrest and apoptosis by a novel retinobenzoic-acid derivative, TAC-101, in human pancreatic-cancer cells. Int. J. Cancer, 81, 637-644.
38. Teelmann,K., Tsukaguchi,T., Klaus,M. and Eliason,J.F. (1993) Comparison of the therapeutic effects of a new arotinoid, Ro 40-8757, and all-trans- and 13-cis-retinoic acids on rat breast cancer. Cancer Res., 53, 2319-2325.
39. Vuligonda,V., Thacher,S.M. and Chandraratna,R.A. (2001) Enantioselective syntheses of potent retinoid X receptor ligands: differential biological activities of individual antipodes. J. Med. Chem., 44, 2298-2303.
40. Kawasaki,H., Eckner,R., Yao,T.P., Taira,K., Chiu,R., Livingston,D.M. and Yokoyama,K.K. (1998) Distinct roles of the co-activators p300 and CBP in retinoic-acid-induced F9-cell differentiation. Nature, 393, 284-289.
41. Leo,C. and Chen,J.D. (2000) The SRC family of nuclear receptor coactivators. Gene, 245, 1-11.
42. Xu,L., Glass,C.K. and Rosenfeld,M.G. (1999) Coactivator and corepressor complexes in nuclear receptor function. Curr. Opin. Genet. Dev., 9, 140-147.
43. Perugini,R.A., McDade,T.P., Vittimberga,F.J.,Jr and Callery,M.P. (1998) The molecular and cellular biology of pancreatic cancer. Crit. Rev. Eukaryot. Gene Expr., 8, 377-393.
44. Xiao,J.H., Ghosn,C., Hinchman,C., Forbes,C., Wang,J., Snider,N., Cordrey,A., Zhao,Y. and Chandraratna,R.A. (2003) APC-independent regulation of beta-catenin degradation via a retinoid X receptor-mediated pathway. J. Biol. Chem., 278, 29954-29962.
45. Ralhan,R. and Kaur,J. (2003) Retinoids as chemopreventive agents. J. Biol. Regul. Homeost. Agents, 17, 66-91.
46. Lotan,R. (2003) Receptor-independent induction of apoptosis by synthetic retinoids. J. Biol. Regul. Homeost. Agents, 17, 13-28.
47. Rishi,A.K., Zhang,L., Boyanapalli,M. et al. (2003) Identification and characterization of a cell cycle and apoptosis regulatory protein-1 as a novel mediator of apoptosis signaling by retinoid CD437. J. Biol. Chem., 278, 33422-33435.
48. Brembeck,F.H., Schoppmeyer,K., Leupold,U., Gornistu,C., Keim,V., Mossner,J., Riecken,E.O. and Rosewicz,S. (1998) A phase II pilot trial of 13-cis retinoic acid and interferon-alpha in patients with advanced pancreatic carcinoma. Cancer, 83, 2317-2323.